Chinese biotech ETFs attract investors amid US$60 billion of licensing deals
Funds from the US are flowing into biotech ETFs as investors seek unique opportunities to beat the market, China AMC’s Heidi Cai says.
Funds from the US are flowing into biotech ETFs as investors seek unique opportunities to beat the market, China AMC’s Heidi Cai says.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
